165 related articles for article (PubMed ID: 30518245)
1. Dopamine receptor heteromers: biasing antipsychotics.
Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245
[No Abstract] [Full Text] [Related]
2. New Concepts in Dopamine D
Urs NM; Peterson SM; Caron MG
Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
[TBL] [Abstract][Full Text] [Related]
3. Investigational dopamine antagonists for the treatment of schizophrenia.
Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
Wilson JM; Sanyal S; Van Tol HH
Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
[TBL] [Abstract][Full Text] [Related]
5. Targeting the dopamine D2 receptor in schizophrenia.
Seeman P
Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
[TBL] [Abstract][Full Text] [Related]
6. Dopamine and antipsychotic drug action revisited.
Jones HM; Pilowsky LS
Br J Psychiatry; 2002 Oct; 181():271-5. PubMed ID: 12356650
[No Abstract] [Full Text] [Related]
7. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
[TBL] [Abstract][Full Text] [Related]
8. Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.
Price R; Salavati B; Graff-Guerrero A; Blumberger DM; Mulsant BH; Daskalakis ZJ; Rajji TK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():83-91. PubMed ID: 24819820
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D(2) receptor blockade in schizophrenia.
Bressan RA; Jones HM; Ell PJ; Pilowsky LS
Am J Psychiatry; 2001 Jun; 158(6):971-2. PubMed ID: 11384924
[No Abstract] [Full Text] [Related]
10. Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
Schwalbe T; Kaindl J; Hübner H; Gmeiner P
Bioorg Med Chem; 2017 Oct; 25(19):5084-5094. PubMed ID: 28666858
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D4 receptors and development of newer antipsychotic drugs.
Kulkarni SK; Ninan I
Fundam Clin Pharmacol; 2000; 14(6):529-39. PubMed ID: 11206702
[TBL] [Abstract][Full Text] [Related]
12. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
13. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2016 Apr; 33(4):1003-17. PubMed ID: 26718955
[TBL] [Abstract][Full Text] [Related]
14. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
15. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
[TBL] [Abstract][Full Text] [Related]
16. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Kapur S; Seeman P
Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor homooligomers and heterooligomers in schizophrenia.
Perreault ML; O'Dowd BF; George SR
CNS Neurosci Ther; 2011 Feb; 17(1):52-7. PubMed ID: 21199449
[TBL] [Abstract][Full Text] [Related]
18. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
Kapur S
Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
[TBL] [Abstract][Full Text] [Related]
19. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
Düring S; Glenthøj BY; Oranje B
Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
